The Pre-FIH Runway Gap
Sectors: Healthcare, Biotech & Strategic Capital · Author: Alexis E.
An analysis of capital deployment bottlenecks between IND clearance and First-In-Human (FIH) clinical milestones in early-stage therapeutic ventures.
Executive Summary
Therapeutic startups routinely face a structural capital cliff during the 9 to 14 months between pre-IND toxicology completion and trial site activation. Traditional Series A syndicates often insist on preliminary human data before committing follow-on capital, while seed syndicates lack the reserves required for clinical manufacturing batches (GMP).
Strategic Signal Indicators
By analyzing FDA 483 response windows, clinical trial registry modifications, and SEC filings for mid-tier CRO capacity, 360 connectAscent tracks early liquidity signals allowing founders and institutional backers to bridge this gap via non-dilutive pharma co-development deals or targeted family office syndication.
"Matching capital to clinical timelines requires timing persuasion around regulatory windows—not spray-and-pray investor outreach."